Bill Ackman Says Valeant Might Change Its Name To Fix Its Reputation

Published: Nov 11, 2016

One option: Take on the well-known name of its largest business, eyecare specialist Bausch & Lomb.

Valeant Pharmaceuticals International, the drugmaker that became a poster child for high drug prices during the U.S. election season, may change its name to help boost its reputation, board member and top investor William Ackman told CNBC on Wednesday.

A name change would be the latest effort by the company to break from its past, after hiring a new chief executive, overhauling the board and exploring billions of dollars in asset sales to pay down a $30 billion debt load.

Back to news